| Closing Price ($) | Shares Out (MM) | Market Cap ($MM) |
| $0.00 | 0 | $0 |
| 8-K | 2020-02-10 | Regulation FD |
| Comps ($ TTM) | Market Cap | Gross Margin | EV/EBITDA | Ret on Assets | Assets | Liabilities | Revenue | G Profit | Net Income | EBITDA | EV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UP Fintech (TIGR) | |||||||||||
| MabVax Therapeutics (MBVXQ) | |||||||||||
| Futu (FHL) | |||||||||||
| Jiayin Group (JFIN) | |||||||||||
| DouYu (DOYU) | |||||||||||
| PURE Bioscience (PURE) | |||||||||||
| FinServ Acquisition (FSRVU) | |||||||||||
| Galileo Acquisition (GLEO) | |||||||||||
| Sirva (SRVA) | |||||||||||
| Tuscan Holdings (THCB) | |||||||||||
| Arete Industries (ARET) | |||||||||||
| Telidyne (TLDN) | |||||||||||
| Bulova Technologies (BTGI) | |||||||||||
| PropTech Acquisition Corp (PTACU) | |||||||||||
| TFF Pharmaceuticals (TFFP) | |||||||||||
| Jumia (JMIA) | |||||||||||
| Adhera Therapeutics (ATRX) | |||||||||||
| Inspyr Therapeutics (NSPX) | |||||||||||
| GSX Techedu (GSX) | |||||||||||
| Tufin Software (TUFN) |
| Balance Sheet ($) | ||
| Cash | ||
| Accounts Receivable | ||
| Inventory | ||
| PP&E | ||
| Assets | ||
| Accounts Payable | ||
| Long-Term Debt | ||
| Liabilities | ||
| Stockholders' Equity | ||
| Income Statement ($) | ||
| Revenue | ||
| Cost of Revenue | ||
| Gross Profit | ||
| R&D | ||
| SG&A | ||
| Tax | ||
| Net Income | ||
| Cash Flow ($) | ||
| Cash Operating | ||
| Cash Investing | ||
| Cash Financing | ||